Summarized by Masters of Longevity from PR Newswire.
Phase II trial found ASC30 reduced HbA1c and body weight versus placebo.
Key Takeaways
- ASC30 showed a 1.7% placebo‑adjusted HbA1c reduction at twelve weeks.
- ASC30 produced 3.8–4.4% placebo‑adjusted weight loss at thirteen weeks.
- Safety was favorable with only mild–moderate AEs and no GI discontinuations.
